AzTrials
AzTrials

Tobacco Use DisorderPhase 2RDECNCT06614504

Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes

A Phase 2 study testing Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes in people with Tobacco Use Disorder, run by University of Vermont at 2 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Read more about this study

Who is it for?
Ages 21 years and olderHealthy volunteers can take part
Conditions the study is for
Tobacco Use Disorder
What is being tested?
Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes
Could I receive a placebo?
No, everyone receives an active treatment
How many people
308 participants
Where
2 sitesUnited States
Study dates
1 Nov 2024to 30 Sep 2028
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Regular use of tobacco
  • 21 year of age or older
  • Speak, comprehend and read English well enough to complete study procedures

Who cannot join

  • Pregnant, trying to become pregnant, or nursing
  • Under the age of 21
  • Health conditions that could undermine ability to complete the study

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

United States2 sites, 2 recruiting
  • University of Vermont

    Burlington, Vermont, 05405

    Emily Booth, (802) 213-8956, emily.booth@med.uvm.edu

    Shirley Plucinski, shirley.plucinski@uvm.edu

    Recruiting
  • Brown University

    Providence, Rhode Island, 02903

    Kim Duguay, 401-863-2988, Kimberly_duguay@brown.edu

    Jennifer Tidey, PhD

    Recruiting

Other trials in United States

About this study

Official title: A Randomized Controlled Trial of Reduced Nicotine Cigarettes and E-cigarettes Among Dual Users

Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Though e-cigarettes are not without risk, completely switching from cigarettes to e-cigarettes likely reduces risk for tobacco-related harm. However, many established dual users maintain long-term smoking and the majority who use e-cigarettes non-daily are at an even greater risk for prolonged smoking than exclusive cigarette smokers. The Food and Drug Administration Center for Tobacco Products (FDA CTP) has announced plans to implement a nicotine-limiting product standard, capping the nicotine in cigarettes at a minimally or non-addictive level. Randomized controlled trials (RCTs) demonstrate that adults who exclusively smoke cigarettes respond to very low nicotine content (VLNC) cigarettes with reductions in smoking, demand, and dependence. However, nicotine reduction RCTs to date have excluded people who regularly use e-cigarettes and therefore it remains unclear how a nicotine-limiting standard for cigarettes would affect smoking among dual users. Given the potential substitutability of e-cigarettes for cigarettes, reducing the nicotine in cigarettes could promote a transition to exclusive e-cigarette use among dual users unable to completely quit nicotine, but only if sufficiently appealing e-cigarettes remain available. E-cigarettes containing 5% nicotine-salt solution are currently most popular in the US, but policy makers have proposed restricting e-cigarettes to ≤ 2% nicotine to curb youth e-cigarette use, and several states have already set limits to reduce nicotine in e-cigarettes. Prior laboratory studies indicate that higher vs lower nicotine e-cigarettes serve as better substitutes for cigarettes among adult dual users. As such, a restriction on e-cigarette nicotine concentration could undermine the potential for e-cigarettes to substitute for cigarettes and diminish the benefits of a nicotine-limiting standard for cigarettes among dual users. This study is a 12-week double-blind 2 cigarette level (Normal Nicotine vs Very Low Nicotine) x 2 e-cigarette level (High Nicotine vs Low Nicotine) between-subjects factorial trial to investigate how a nicotine-limiting standard for cigarettes affects adult dual users and whether these effects are impacted by constraints on e-cigarette nicotine concentration. Outcome measures include cigarettes per day, cigarette dependence, and toxicant exposure. The research is highly relevant to FDA CTP domains of Addiction and Behavior because it will test whether reducing the nicotine content of cigarettes reduces smoking and dependence, and whether these effects are moderated by the availability of high vs low nicotine e-cigarettes.

Being tested
Varying the nicotine content of cigarettes, Varying the nicotine content of e-cigarettes
Keywords
Cigarettes, E-cigarettes
Medical subject headings
Tobacco Use Disorder, Vaping

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Varying the nicotine content of cigarettesOther

    Also called Comparing normal nicotine content (RC 1) to very low nicotine content (RC 2)

    Altering the nicotine content of the tobacco research cigarettes

  • Varying the nicotine content of e-cigarettesOther

    Also called Comparing high nicotine content (REC 1) to low nicotine content (REC 2)

    Altering the nicotine content of the research e-cigarettes

Study groups in NCT06614504
Study groupRoleWhat they receive
RC 1 + REC 1ExperimentalResearch cigarettes #1 plus research e-cigarettes #1
Receives: Other: Varying the nicotine content of cigarettes; Other: Varying the nicotine content of e-cigarettes
RC 1 + REC 2ExperimentalResearch cigarettes #1 plus research e-cigarettes #2
Receives: Other: Varying the nicotine content of cigarettes; Other: Varying the nicotine content of e-cigarettes
RC 2 + REC 1ExperimentalResearch cigarettes #2 plus research cigarettes #1
Receives: Other: Varying the nicotine content of cigarettes; Other: Varying the nicotine content of e-cigarettes
RC 2 + REC 2ExperimentalResearch cigarettes #2 + research e-cigarettes #2
Receives: Other: Varying the nicotine content of cigarettes; Other: Varying the nicotine content of e-cigarettes

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of cigarettes smoked per day

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Sep 2024
  2. Study start1 Nov 2024
  3. Primary completion31 Aug 2028 (estimated)
  4. Study completion30 Sep 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Other
Allocation
Randomised
Intervention model
Factorial
Model description
2x2 factorial randomized controlled trial
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
308 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06614504
Sponsor's protocol ID
R01DA059562
Acronym
RDEC
Status last verified
Sep 2024
First submitted
23 Sep 2024
Last updated
27 Jun 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be made available once we have published the results of the parent trials and manuscripts based on secondary analyses of those data, which we anticipate taking approximately three years.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes in people with Tobacco Use Disorder, run by University of Vermont at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Emily Booth (802-656-1641, emily.booth@med.uvm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of cigarettes smoked per day (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in